18221 Investors following Aurobindo Pharm. Share this News with them.
0
Like this story, share it with millions of investors on M3
Aurobindo gets approval for Didanosine Delayed Release Cap
Aurobindo Pharma Limited is pleased to announce that the company has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Didanosine Delayed Release (Enteric-Coated) Capsules 125mg, 200mg, 250mg and 400mg
Aurobindo Pharma Limited is pleased to announce that the company has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Didanosine Delayed Release (Enteric-Coated) Capsules 125mg, 200mg, 250mg and 400mg
Didanosine Delayed Release Capsules is the generic version of Bristol Myer Squibb's Videx® EC (Didanosine) Delayed-release Capsules, 125mg, 200mg, 250mg and 400mg and is indicated for the treatment of HIV-1 infections in adults.
This is Aurobindo's 78th ANDA approval from the USFDA
|
Budget: 2008, 2009, 2010, 2011, 2012 |
Intuit Money Manager |
RBI Credit Policy | Union Budget | Budget 2012
| Economic Survey
| Railway Budget
| Financial Glossary
|
Message Board |
Moneybhai |
Connect.in.com |
Business Yellow Pages |
India's Premiere Technology Guide | History India
| Up Polls | Latest News
| Uninor | Tata Steel | BSE Sensex | Aurobindo Pharma | Namma Metro | Mahindra Satyam | Chennai | Reliance Industries | Iran | Vodafone Essar 
